^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

MCARH125

i
Other names: MCARH125
Associations
Company:
Memorial Sloan-Kettering Cancer Center
Drug class:
BCMA-targeted CAR-T immunotherapy
Related drugs:
Associations
5ms
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma (clinicaltrials.gov)
P1, N=24, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
SDC1 (Syndecan 1)
|
MCARH109 • MCARH125